NEW YORK (GenomeWeb) – iCubate announced yesterday that it has received CE mark for its first clinical assay, the iC-GPC assay and its platform, the iC-System, used for the rapid diagnosis of pathogenic bacteria associated with bloodstream infection. The CE mark provides an entry for iCubate to begin market integration into the European Union.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.